News Releases

Date Title and Summary View
Dec 14, 2018
Statement on Reuters Talc Article
NEW BRUNSWICK, N.J. , Dec. 14, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free.
Dec 12, 2018
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
84.5 percent of patients receiving TREMFYA achieved the primary endpoint of a PASI 90 response at week 48 compared with 70.0 percent of patients receiving Cosentyx ECLIPSE is the first Phase 3 head-to-head study to compare efficacy between the first-in-class IL-23 inhibitor, TREMFYA, and the IL-17
Dec 04, 2018
Dec 03, 2018
Dec 03, 2018
Dec 03, 2018
Nov 26, 2018
Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference
NEW BRUNSWICK, N.J. , Nov. 26, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12 th , at The Mandarin Oriental, New York.  Ciro Römer, Company Group Chairman for the Johnson & Johnson Medical
Nov 16, 2018
Nov 15, 2018
Nov 12, 2018
Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference
NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace Hotel in New York City.  Joseph J. Wolk , Executive Vice President and Chief Financial
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.